If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled ...
If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment CSU is a chr ...
Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and symptoms, and systemic corticosteroid use or surgery comp ...
Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment ...
Revolo completes patient enrollment in phase 2 trial of ‘1104 in eosinophilic esophagitis: New Orleans Wednesday, September 14, 2022, 14:30 Hrs [IST] Revolo Biotherapeutics (Rev ...
BROADEN2 Phase 2b trial in atopic dermatitis (AD) ongoing, with data expected by mid-2027KT-621 BREADTH Phase 2b trial in asthma ...
Learn more about whether Celldex Therapeutics, Inc. or Veracyte, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
US FDA approves Sanofi and Regeneron’s Dupixent for allergic fungal rhinosinusitis: Paris Thursday, February 26, 2026, 15:00 Hrs [IST] The US Food and Drug Administration (FDA) ...
Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitisApproval in adults and children aged 6 years and older supported by phase 3 study ...
FARE's indicator report tracks the growing public health challenge of food allergy in the United States—a top-tier public ...
Frequent dry eyes may signal more than simple irritation and could be an early warning sign of an autoimmune disease. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results